Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market.
Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian Research Promotion Agency to extend its technology to cancer immunotherapies. This amount is huge for a government grant, so what makes this technology better than the many other cancer immunotherapies out there?
Hookipa’s VaxWave and TheraT platforms can induce unprecedentedly strong immune responses in both B-cells and T-cells. Unlike other vaccines, the company’s viral vectors don’t generate antibodies against them and can be used more than once to boost the immune system.
With the new funds, Hookipa will advance HB201, a vaccine for human papilloma virus (HPV). The target is head and neck squamous cell cancer (HNSCC), which affects over 500,000 people globally.